The Medical Letter on Drugs and Therapeutics
Eloctate for Hemophilia A
October 12, 2015 (Issue: 1479)The FDA has approved Eloctate (Biogen), a recombinant factor VIII Fc fusion protein with an extended half-life, for use in adults and children with hemophilia A. Eloctate is indicated for control and prevention of bleeding episodes, perioperative...more
- A Srivastava et al. Guidelines for the management of hemophilia. Haemophilia 2013; 19:e1.
- ME Mancuso and PM Mannucci. Fc-fusion technology and recombinant FVIII and VIX in the management of the hemophilias. Drug Des Devel Ther 2014; 8:365.
- J Mahlangu et al. Phase 3 study of recombinant factor VIII Fc fusion protein in severe hemophilia A. Blood 2014; 123:317.
- PM Mannucci et al. How we choose factor VIII to treat hemophilia. Blood 2012; 119:4108.
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.